IMCR vs. VRNA, TLX, TGTX, GRFS, LNTH, LEGN, AXSM, NUVL, ADMA, and PCVX
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Immunocore vs.
Verona Pharma (NASDAQ:VRNA) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Verona Pharma has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verona Pharma had 7 more articles in the media than Immunocore. MarketBeat recorded 14 mentions for Verona Pharma and 7 mentions for Immunocore. Verona Pharma's average media sentiment score of 1.37 beat Immunocore's score of 1.36 indicating that Verona Pharma is being referred to more favorably in the media.
85.9% of Verona Pharma shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 4.8% of Verona Pharma shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Verona Pharma currently has a consensus target price of $81.50, suggesting a potential upside of 10.00%. Immunocore has a consensus target price of $58.13, suggesting a potential upside of 83.59%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Verona Pharma.
Verona Pharma received 263 more outperform votes than Immunocore when rated by MarketBeat users. Likewise, 80.96% of users gave Verona Pharma an outperform vote while only 73.74% of users gave Immunocore an outperform vote.
Verona Pharma has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Verona Pharma has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Verona Pharma's return on equity.
Summary
Verona Pharma beats Immunocore on 11 of the 19 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
This page (NASDAQ:IMCR) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy IMCR Stock Free IMCR Stock Alerts